The role of insulin‐like growth factor‐I and its binding proteins in glucose homeostasis and type 2 diabetes
Citations Over TimeTop 10% of 2009 papers
Abstract
This review addresses the possible role of the insulin-like growth factor (IGF)-axis in normal glucose homoeostasis and in the etiopathogenesis of type 2 diabetes. IGF-I, a peptide hormone, shares amino acid sequence homology with insulin and has insulin-like activity; most notably, the promotion of glucose uptake by peripheral tissues. Type 2 diabetes as well as pre-diabetic states, including impaired fasting glucose and impaired glucose tolerance, are associated cross-sectionally with altered circulating levels of IGF-I and its binding proteins (IGFBPs). Administration of recombinant human IGF-I has been reported to improve insulin sensitivity in healthy individuals as well as in patients with insulin resistance and type 2 diabetes. Further, IGF-I may have beneficial effects on systemic inflammation, a risk factor for type 2 diabetes, and on pancreatic beta-cell mass and function. There is considerable inter-individual heterogeneity in endogenous levels of IGF-I and its binding proteins; however, the relationship between these variations and the risk of developing type 2 diabetes has not been extensively investigated. Large prospective studies are required to evaluate this association.
Related Papers
- → Nonalcoholic Fatty Liver Disease, Hepatic Insulin Resistance, and Type 2 Diabetes(2013)725 cited
- → The ventromedial hypothalamic nucleus: watchdog of whole-body glucose homeostasis(2022)45 cited
- → The impact of hypoxia exposure on glucose homeostasis in metabolically compromised humans: A systematic review(2021)23 cited
- → Pharmacological strategies for preventing type 2 diabetes inpatients with impaired glucose tolerance(2013)8 cited
- → Adipocytokine levels in nonalcoholic fatty liver disease #(2009)